Literature DB >> 2776822

Comparison of trimethadione and antipyrine as indicators of oxidative drug metabolizing capacity in man.

E Tanaka1, K Nakamura.   

Abstract

Ten healthy male volunteers were given trimethadione (TMO) 4 mg/kg and antipyrine (AP) 500 mg alone or concomitantly to determine whether the metabolism of the drugs was mediated by the same or closely related forms of cytochrome P-450. Whether administered alone or together the clearance (CL) and half-life (t 1/2) of TMO and AP were the same, and there was a good correlation between the CL and t 1/2 of TMO and AP (alone r = 0.755 and 0.623, respectively; coadministered r = 0.771 and 0.503, respectively). Excretion of AP and its main metabolite and the clearance for production of AP metabolites after AP was administered alone were not significantly different when TMO and AP were taken together. When the two drugs were administered alone or coadministered, the correlation between the CL of TMO and the excretion of 3-hydroxymethyl-3-norantipyrine (NORA) was close (alone r = 0.734, coadministered r = 0.749). The correlation between the CL of TMO and CLm of NORA when TMO and AP were given alone or concomitantly was 0.762 and 0.772, respectively. The findings suggest that TMO metabolism and the formation of NORA in healthy subjects are mediated by a closely related form(s) of the cytochrome P-450 system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2776822     DOI: 10.1007/BF00637749

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Simultaneous determination of serum trimethadione and its metabolite by gas chromatography.

Authors:  E Tanaka; S Misawa
Journal:  J Chromatogr       Date:  1987-01-23

2.  Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism.

Authors:  M Døssing; H Pilsgaard; B Rasmussen; H E Poulsen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

4.  Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine.

Authors:  M W Teunissen; J E Meerburg-van der Torren; N P Vermeulen; D D Breimer
Journal:  J Chromatogr       Date:  1983-12-09

5.  Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.

Authors:  M Danhof; A van Zuilen; J K Boeijinga; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Interindividual differences in drug oxidation: clinical importance.

Authors:  F Sjöqvist; C von Bahr
Journal:  Drug Metab Dispos       Date:  1973 Jan-Feb       Impact factor: 3.922

7.  Hepatic trimethadione-oxidizing capacity remains normal in patients with extrahepatic cholelithiasis.

Authors:  E Tanaka; A Ishikawa; A Ono; A Takada; T Okamura; S Misawa
Journal:  J Pharmacobiodyn       Date:  1986-05

8.  Studies on theophylline metabolism: autoinduction and inhibition by antipyrine.

Authors:  C L Denlinger; K K Stryker; L B Slusher; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

9.  Age-related changes in trimethadione oxidizing capacity.

Authors:  E Tanaka; A Ishikawa; A Ono; T Okamura; S Misawa
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

10.  Trimethadione tolerance test for evaluation of functional reserve of the liver in patients with liver cirrhosis and esophageal varices.

Authors:  E Tanaka; A Ishikawa; A Ono; T Okamura; S Kobayashi; H Yasuhara; S Misawa
Journal:  J Pharmacobiodyn       Date:  1986-03
View more
  1 in total

1.  Clinical significance of the trimethadione tolerance test in chronic hepatitis: a useful indicator of hepatic drug metabolizing capacity.

Authors:  M Abei; E Tanaka; N Tanaka; Y Matsuzaki; T Ikegami; A Ishikawa; T Osuga
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.